All News
Best Rheumatologists (7.19.2024)
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Read Article
JAK Inhibitors Reduce Macular Degeneration
d
Mepage Today
Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.
Read Article
Geography of Arthritis-attributable Pain in the USA
The journal Pain has shown geographic differences in arthritis-attributable pain, arthritis-related outcomes mostly clustered in the Deep South and Appalachia, while severe arthritis pain is more prevalent in the Southwest, Pacific Northwest, Georgia, Florida, and Maine.
Read Article
Top 20 Best Rheumatology Hospitals - 2024
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot.
Read Article
268/279 SLE pts w/ kidney biopsy for proteinuria were Dx w/ lupus nephritis. Proliferative LN (III/IV+V) had higher levels of C1q, chromatin, dsDNA, ribosomal P Abs. C1q & dsDNA independently assoc w/ proliferative LN. AutoAbs decreased in proliferative LN https://t.co/oq3JhrFlz8 https://t.co/nxQBZvoOzP
Dr. John Cush RheumNow ( View Tweet)
Full read overview of myositis associated - ILD (and treatments), including:
- Case examples
- Antisynthetase Syndrome
- Anti-MDA5 Amyopathic DM
- Interstitial Lung Disease in Myositis https://t.co/PhfuuBHOYf https://t.co/OC1GmWkYyO
Dr. John Cush RheumNow ( View Tweet)
Problems With Laboratory Tests in the Management of RA
https://t.co/kUYivP7SHW https://t.co/nFtB75N0jQ
Dr. John Cush RheumNow ( View Tweet)
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on https://t.co/V10S4oVFsv. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/gL38TVZRkM to stay at the forefront of medical innovation. https://t.co/cZontmAPTq
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Metrics Used by Rheumatologists in RA
https://t.co/7Qr4cYvqp1 https://t.co/1FnyNpfhqi
Dr. John Cush RheumNow ( View Tweet)
Pain in RA: Different Drugs for Different Mechanisms
https://t.co/pOETFkTIkS https://t.co/Vn5zgrYsKR
Dr. John Cush RheumNow ( View Tweet)
Top 20 Best Rheumatology Hospitals - 2024
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot.
https://t.co/ZHogsqVR5H https://t.co/45qm4Li4ii
Dr. John Cush RheumNow ( View Tweet)
Study of 478 CA pts Rx w. anti-PD-(L)1 Ab or anti-CTLA4 Ab - 28 (6%) had pre-existing Autoimmune Dz (AI). irAE (w/ checkpoint inhib) were higher w/ preexisting AI (57% vs 35%), but activity of AI was not related to irAEs occurrence.
https://t.co/CHIdaH91qR https://t.co/XuaLk4D205
Dr. John Cush RheumNow ( View Tweet)
Prospective cohort study from 474 055 participants in UK Biobank, finds long-term exposure to air pollutants, NO2 etc, assoc w/ a 19% to 47% increased risk incident psoriasis. Air pollution and genetic predisposition also significantly incr incident PsO https://t.co/ogX81ybU3l https://t.co/Mvd6tAj2j6
Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitor Brodalumab is not often talked about, but its approved for PsO & PsA. German study of 227 PsO w/ 37 PsA pts Rx w/ BRO - good, rapid response by 3 mos. 1 year drug survival rate was 76.2%, (mean discontinuation=8.3 mos. https://t.co/4byFoc96Zs https://t.co/sPomX0s8aa
Dr. John Cush RheumNow ( View Tweet)
192 RA pts on MTX: GI Sxs studied w/ MISS (MTX intolerance severity score). GI intolerance seen in 56%, Nausea & pain post-MTX most common. More in afro-descendants, w/ FM, Steroids, or JAKi. MISS results unrelated to Route, Gi Dz, age, MTX dose https://t.co/EROmZQo1Zs https://t.co/SOMzzXXj0b
Links:
Dr. John Cush RheumNow ( View Tweet)
Updated EULAR Recommendations on the Treatment of Systemic Sclerosis
Medscape has published an overview to the 2024 updated recommendations for the treatment of SSc presented in Vienna at EULAR 2024.
https://t.co/U0usOgajFQ https://t.co/Hos3mu7rVE
Dr. John Cush RheumNow ( View Tweet)
ACR Comments on CMS Proposed 2025 Physician Payment Rule
The American College of Rheumatology (ACR) shared the following initial reaction to the proposed CY 2025 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program rule.
https://t.co/l5aUWiCtQE https://t.co/7jQdouVRbm
Dr. John Cush RheumNow ( View Tweet)
Febuxostat is assoc w/ a reduced risk of kidney events and slower decline in eGFR. Metanalysis of 16 RCTs, shows febuxostat w/a reduced risk of kidney events (RR=0.56) & slower decline in eGFR; & reduced urine albumin to creatinine ratio https://t.co/GQ8UopbA88 https://t.co/WQskc1yZ02
Dr. John Cush RheumNow ( View Tweet)
IRIS-RA, a failed phase 2 study of Nipocalimab, an anti-FcRn mAb severe active RA not responding to TNFi. 53 seropos. RA pts did not achieve primary endpt of better DAS28-CRP at Wk 12 (but Nipo was numerically better & signif lowered RF, CCP, but not CRP) https://t.co/52HLsfpKLS https://t.co/eEifXA6MpP
Dr. John Cush RheumNow ( View Tweet)
Pathogenesis of Autoimmune Liver Disease (ALDs)
ALDs, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage
https://t.co/acgwwglKve https://t.co/ZDpF1VhBlc
Dr. John Cush RheumNow ( View Tweet)